Foundations Investment Advisors LLC Sells 528 Shares of Veeva Systems Inc. $VEEV

Foundations Investment Advisors LLC lessened its holdings in Veeva Systems Inc. (NYSE:VEEV) by 24.3% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 1,649 shares of the technology company’s stock after selling 528 shares during the period. Foundations Investment Advisors LLC’s holdings in Veeva Systems were worth $475,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in VEEV. Nuveen LLC bought a new stake in Veeva Systems in the first quarter valued at about $365,684,000. Price T Rowe Associates Inc. MD lifted its stake in Veeva Systems by 20.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock worth $924,754,000 after purchasing an additional 689,700 shares during the period. Los Angeles Capital Management LLC boosted its holdings in Veeva Systems by 423.8% during the second quarter. Los Angeles Capital Management LLC now owns 841,303 shares of the technology company’s stock valued at $242,278,000 after purchasing an additional 680,702 shares in the last quarter. Linonia Partnership LP grew its stake in shares of Veeva Systems by 52.7% in the 1st quarter. Linonia Partnership LP now owns 1,836,557 shares of the technology company’s stock valued at $425,402,000 after purchasing an additional 633,585 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Veeva Systems by 48.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,799,931 shares of the technology company’s stock worth $416,918,000 after buying an additional 585,785 shares in the last quarter. Institutional investors and hedge funds own 88.20% of the company’s stock.

Veeva Systems Stock Down 1.2%

Veeva Systems stock opened at $273.82 on Wednesday. The stock has a 50-day simple moving average of $288.61 and a 200 day simple moving average of $278.56. The stock has a market capitalization of $44.88 billion, a price-to-earnings ratio of 56.23, a P/E/G ratio of 2.22 and a beta of 0.98. Veeva Systems Inc. has a 12-month low of $201.54 and a 12-month high of $310.50.

Veeva Systems (NYSE:VEEV) last posted its quarterly earnings data on Wednesday, August 27th. The technology company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.90 by ($0.64). Veeva Systems had a net margin of 27.29% and a return on equity of 13.72%. The company had revenue of $789.08 million during the quarter, compared to analyst estimates of $768.49 million. During the same quarter in the previous year, the business posted $1.62 EPS. The company’s revenue was up 16.7% compared to the same quarter last year. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. As a group, sell-side analysts anticipate that Veeva Systems Inc. will post 4.35 EPS for the current year.

Insider Buying and Selling

In other news, insider Thomas D. Schwenger sold 3,350 shares of the business’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the completion of the sale, the insider owned 23,773 shares in the company, valued at $7,132,850.92. The trade was a 12.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total value of $1,839,720.00. Following the completion of the transaction, the insider owned 25,325 shares in the company, valued at approximately $7,765,151.50. This represents a 19.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 24,665 shares of company stock worth $7,438,000 in the last quarter. Insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on VEEV shares. Oppenheimer reaffirmed an “outperform” rating and issued a $325.00 price target on shares of Veeva Systems in a research note on Thursday, August 28th. Citigroup lifted their price objective on Veeva Systems from $329.00 to $349.00 and gave the company a “buy” rating in a report on Thursday, August 28th. BTIG Research reaffirmed a “buy” rating and issued a $340.00 target price on shares of Veeva Systems in a report on Friday, October 17th. Raymond James Financial reiterated an “outperform” rating and set a $340.00 target price (up previously from $310.00) on shares of Veeva Systems in a research report on Thursday, August 28th. Finally, Needham & Company LLC restated a “buy” rating and issued a $355.00 price target on shares of Veeva Systems in a research report on Friday, October 17th. Seventeen analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Veeva Systems currently has a consensus rating of “Moderate Buy” and an average price target of $307.28.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.